HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

News Hansoh Pharmaceutical Group Company Limited OTC Markets

Equities

HNSPF

KYG549581067

Market Closed - OTC Markets Other stock markets 03:54:35 2024-03-20 pm EDT			5-day change	1st Jan Change
1.88 ^USD	+19.75%		-.--%	+2.73%

Apr. 30	Hansoh Pharmaceutical’s 2023 Profit Up 27%	MT
Apr. 29	Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansoh Pharmaceutical’s 2023 Profit Up 27%	Apr. 30	MT
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024	Apr. 29	CI
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	Apr. 03	MT
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	Apr. 03	CI
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024	Mar. 26	CI
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01	Mar. 14	MT
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules	Feb. 08	MT
Hansoh Pharmaceutical Buys Back 3 Million Shares	Jan. 31	MT
Fed, China Property Outlooks Roil Asian Stock Markets	Jan. 30	MT
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	Jan. 24	AQ
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug	Jan. 23	MT
China Outlook, Tech Rally Roils Asian Stock Markets	Jan. 19	MT
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment	Jan. 17	MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets	Jan. 17	CI
Federal Reserve Outlook Mutes Asian Stock Markets	Jan. 05	MT
Hansoh Pharmaceutical’s Trustee Buys Back Shares	Jan. 02	MT
GSK plc Enters Exclusive License Agreement with Hansoh for HS-20093	Dec. 20	CI
GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody	Dec. 20	DJ
Hansoh Pharmaceutical Grants GSK Subsidiary Marketing License for Tumor Drug HS-20093	Dec. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hansoh Pharmaceutical Group Company Limited OTC Markets

Equities

HNSPF

KYG549581067

Summary

Filters